As of June 1, 2025, Tibet Weixinkang Medicine Co Ltd (603676.SS) reports a Net Margin of 18.93%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Tibet Weixinkang Medicine Co Ltd's Net Margin
Over recent years, Tibet Weixinkang Medicine Co Ltd's Net Margin has shown significant volatility. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | 18.93% |
| 2023-12-31 | 16.18% |
| 2022-12-31 | 12.65% |
| 2021-12-31 | 9.28% |
| 2020-12-31 | 8.16% |
This slight upward trend highlights how Tibet Weixinkang Medicine Co Ltd manages its overall profitability and cost control over time.
Comparing Tibet Weixinkang Medicine Co Ltd's Net Margin to Peers
To better understand Tibet Weixinkang Medicine Co Ltd's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Tibet Weixinkang Medicine Co Ltd (603676.SS) | 18.93% |
| Jiangsu Jibeier Pharmaceutical Co Ltd (688566.SS) | 24.46% |
| Zhejiang Cheng Yi Pharmaceutical Co Ltd (603811.SS) | 24.25% |
| Hunan Hansen Pharmaceutical Co Ltd (002412.SZ) | 21.93% |
| Zhejiang Jolly Pharmaceutical Co Ltd (300181.SZ) | 19.70% |
| Jinghua Pharmaceutical Group Co Ltd (002349.SZ) | 15.17% |
Compared to its competitors, Tibet Weixinkang Medicine Co Ltd's Net Margin is among the highest compared to peers, suggesting strong overall cost management and pricing power.